FrancophonIA/ELRC3.0 huggingface dataset:
English: The population pharmacokinetic analysis in pulmonary arterial hypertension patients suggested that co-administration of beta-blockers in combination with CYP3A4 substrates might result in an additional increase in sildenafil exposure compared with administration of CYP3A4 substrates alone.
Croatian: Analiza populacijske farmakokinetike u bolesnika s plućnom arterijskom hipertenzijom upućuje na to da istovremena primjena beta-blokatora u kombinaciji sa supstratima CYP3A4 može rezultirati dodatnim povećanjem izloženosti sildenafilu u usporedbi s primjenom samo supstrata CYP3A4.
English: The overall frequency of discontinuation in sildenafil treated patients at doses of 20 mg, 40 mg and 80 mg TID was 2.9%, 3.0% and 8.5% respectively, compared to 2.9% with placebo.
Croatian: Ukupna učestalost prekida liječenja u bolesnika liječenih sildenafilom u dozama od 20 mg, 40 mg i 80 mg TID iznosila je 2,9%, 3,0% odnosno 8,5%, u odnosu na 2,9% kod primjene placeba.
English: The efficacy of sildenafil has not been established in patients with severe pulmonary arterial hypertension (functional class IV).
Croatian: Nije utvrđena djelotvornost sildenafila u bolesnika s teškom plućnom arterijskom hipertenzijom (funkcionalni stupanj IV).
English: How to store Granpidam
Croatian: Kako čuvati Granpidam
English: - Medicines containing nitrates, or nitric oxide donors such as amyl nitrate (“poppers”).
Croatian: - lijekove koji sadrže nitrate ili donore dušikova oksida poput amil nitrata.
English: Population pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data indicated a reduction in sildenafil clearance and/or an increase of oral bioavailability when co-administered with CYP3A4 substrates and the combination of CYP3A4 substrates and beta-blockers.
Croatian: Analiza podataka o populacijskoj farmakokinetici iz kliničkih ispitivanja u plućnoj arterijskoj hipertenziji ukazala je na smanjen klirens i/ili povećanu bioraspoloživost sildenafila nakon peroralne primjene kada se ovaj lijek primjenjivao zajedno sa supstratima CYP3A4 i kombinacijom supstrata CYP3A4 i beta-blokatora.
English: In patients with pulmonary arterial hypertension, the average steady state concentrations were 20-50% higher over the investigated dose range of 20-80 mg three times a day compared to healthy volunteers.
Croatian: U bolesnika s plućnom arterijskom hipertenzijom, prosječne koncentracije u stanju dinamičke ravnoteže su u ispitivanom rasponu doza od 20-80 mg tri puta na dan bile 20-50% više nego u zdravih dobrovoljaca.
English: Metabolism and nutrition disorders Common fluid retention
Croatian: Poremećaji metabolizma i prehrane često retencija tekućine
English: Side effects reported commonly (may affect up to 1 in 10 people) included: infection under the skin, flu-like symptoms, inflammation of the sinuses, reduced number of red blood cells (anaemia), fluid retention, difficulty sleeping, anxiety, migraine, shaking, “pins and needles”-like sensation, burning sensation, reduced sense of touch, bleeding at the back of the eye, effects on vision, blurred vision and light sensitivity, effects on colour vision, eye irritation, bloodshot eyes /red eyes, vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose, stomach inflammation, gastroenteritis, heartburn, piles, abdominal distension, dry mouth, hair loss, redness of the skin, night sweats, muscle aches, back pain and increased body temperature.
Croatian: Nuspojave koje su prijavljene često (mogu se javiti u do 1 na 10 osoba) bile su: infekcija pod kožom, simptomi nalik gripi, upala sinusa, smanjen broj crvenih krvnih stanica (anemija), zadržavanje tekućine, poteškoće sa spavanjem, tjeskoba, migrena, tresavica, osjećaj bockanja i trnjenja, osjećaj žarenja, smanjen osjet dodira, krvarenje u stražnjem dijelu oka, učinci na vid, zamagljen vid i osjetljivost na svjetlost, učinci na raspoznavanje boja, iritacije očiju, zakrvavljene oči/crvene oči, vrtoglavica, bronhitis, krvarenje iz nosa, curenje iz nosa, kašalj, začepljen nos, upala želuca, gastroenteritis, žgaravica, hemoroidi, nadimanje trbuha, suha usta, gubitak kose, crvenilo kože, noćno znojenje, bolovi u mišićima, bol u leđima i povišena tjelesna temperatura.
English: Of the total 229 subjects who received sildenafil, there were 55, 74, and 100 subjects in the low, medium and high dose groups, respectively.
Croatian: Od ukupno 229 ispitanika koji su primali sildenafil, 55 ispitanika bilo je u skupini s niskom, 74 ispitanika u skupini sa srednjom i 100 ispitanika u skupini s visokom dozom.
English: The exposure to sildenafil in patients on CYP3A4 substrates and CYP3A4 substrates plus beta-blockers was 43% and 66% higher, respectively, compared to patients not receiving these classes of medicines.
Croatian: Izloženost sildenafilu u bolesnika koji su uzimali supstrate CYP3A4 bila je 43% veća, a u onih koji su uzimali supstrate CYP3A4 s betablokatorima 66% veća u usporedbi s bolesnicima koji nisu uzimali lijekove iz navedenih skupina.
English: Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).
Croatian: Istovremena upotreba riocigvata sa PDE5 inhibitorima, uključujući sildenafil je kontraindicirana (vidjeti dio 4.3).
English: Doses up to 80 mg TID were administered and after 3 years 68% of 133 patients on study treatment were receiving sildenafil 80 mg TID.
Croatian: Primjenjivale su se doze do 80 mg tri puta na dan te je nakon 3 godine 68% od 133 bolesnika liječenih ispitivanim lijekom primalo sildenafil u dozi od 80 mg TID.
English: For paediatric patients aged 1 year to 17 years old, the recommended dose in patients ≤20 kg is 10 mg three times a day and for patients >20 kg is 20 mg three times a day.
Croatian: Za pedijatrijske bolesnike u dobi od 1 do 17 godina preporučena doza u bolesnika tjelesne težine ≤ 20 kg iznosi 10 mg tri puta na dan, a u bolesnika tjelesne težine > 20 kg ona iznosi 20 mg tri puta na dan.
English: In this population, Kaplan-Meier estimates of 1, 2 and 3 year survival were 96%, 91% and 82%, respectively.
Croatian: U ovoj je populaciji jednogodišnje preživljenje procijenjeno Kaplan-Meierovom metodom iznosilo 96%, dvogodišnje 91%, a trogodišnje 82%.
English: Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.
Croatian: Stoga inhibitori tih izoenzima mogu smanjiti klirens sildenafila, dok ga njihovi induktori mogu povećati.
English: Each tablet contains 20 mg of sildenafil (as citrate).
Croatian: Jedna tableta sadrži 20 mg sildenafila (u obliku sildenafilcitrata).
English: In post-marketing experience with sildenafil for male erectile dysfunction, serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported in temporal association with the use of sildenafil.
Croatian: Nakon stavljanja u promet sildenafila u liječenju muške erektilne disfunkcije prijavljeni su ozbiljni kardiovaskularni događaji, uključujući infarkt miokarda, nestabilnu anginu, iznenadnu srčanu smrt, ventrikularnu aritmiju, cerebrovaskularno krvarenje, prolaznu ishemijsku ataku, hipertenziju i hipotenziju, koji su bili vremenski povezani s primjenom sildenafila.
English: Women of childbearing potential and contraception in males and females Due to lack of data on effects of sildenafil in pregnant women, Granpidam is not recommended for women of childbearing potential unless also using appropriate contraceptive measures.
Croatian: Zbog nedostatka podataka o učincima sildenafila u trudnica ne preporučuje se primjena lijeka Granpidam u žena reproduktivne dobi, osim ako istovremeno ne primjenjuju odgovarajuće mjere kontracepcije.
English: Side effects reported uncommonly (may affect 1 in 100 people) included: reduced sharpness of vision, double vision, abnormal sensation in the eye, penile bleeding, presence of blood in semen and/or urine, and breast enlargement in men.
Croatian: Nuspojave koje su prijavljene manje često (mogu se javiti u do 1 na 100 osoba) bile su: smanjena oštrina vida, dvoslike, neuobičajeni osjeti u oku, krvarenje iz penisa, prisutnost krvi u sjemenoj tekućini i/ili mokraći i povećanje dojki u muškaraca.
English: Dose adjustments for sildenafil may be required when co-administered with CYP3A4 inducers (see section 4.5).
Croatian: Možda će biti potrebno prilagoditi dozu sildenafila kada se primjenjuje istovremeno s induktorima CYP3A4 (vidjeti dio 4.5).
English: A mean placebo corrected increase in walk distance of 26 metres was observed in favour of sildenafil (95% CI: 10.8, 41.2) (p = 0.0009).
Croatian: Opaženo je prosječno, za placebo korigirano povećanje prehodane udaljenosti od 26 metara u korist sildenafila (95% CI: 10,8; 41,2) (p = 0,0009).
English: Sildenafil exposure was 5-fold higher at a dose of 80 mg three times a day compared to the exposure at a dose of 20 mg three times a day.
Croatian: Izloženost sildenafilu pri dozi od 80 mg tri puta na dan bila je peterostruko veća u odnosu na izloženost pri dozi od 20 mg tri puta na dan.
English: Subjects were allocated to one of three sildenafil treatment groups, low (10 mg), medium (10-40 mg) or high dose (20-80 mg) regimens of sildenafil given three times a day, or placebo.
Croatian: Ispitanici su razvrstani u jednu od tri skupine koje su primale sildenafil: nisku (10 mg), srednju (10-40 mg) ili visoku dozu (20-80 mg) sildenafila tri puta na dan, ili u skupinu koja je primala placebo.
English: Blood and lymphatic system disorders Common anaemia
Croatian: Poremećaji krvi i limfnog sustava gastroenteritis često anemija
English: The known adverse reactions headache, flushing, pain in extremity and oedema were noted in a higher frequency in sildenafil/epoprostenol treated patients compared to placebo/epoprostenol treated patients.
Croatian: Učestalost poznatih nuspojava: glavobolje, navale crvenila, boli u ekstremitetima i edema bila je veća u bolesnika liječenih sildenafilom/epoprostenolom u usporedbi s bolesnicima koji su primali placebo/epoprostenol.
English: A population pharmacokinetic analysis of sildenafil data from adult PAH patients in clinical trials including a 12 week study to assess the efficacy and safety of oral sildenafil 20 mg three times a day when added to a stable dose of bosentan (62.5 mg-125 mg twice a day) indicated a decrease in sildenafil exposure with bosentan co-administration, similar to that observed in healthy volunteers (see sections 4.4 and 5.1).
Croatian: Analiza podataka o populacijskoj farmakokinetici sildenafila u odraslih bolesnika s PAH-om iz kliničkih ispitivanja, uključujući 12-tjedno ispitivanje za procjenu djelotvornosti i sigurnosti peroralnog sildenafila 20 mg tri puta dnevno koji se dodaje stabilnoj dozi bosentana (62,5 mg - 125 mg dvaput dnevno) pokazala je da se izloženost sildenafilu smanjila kod istovremene primjene bosentana, slično onome što je primijećeno u zdravih dobrovoljaca (vidjeti dijelove 4.4 i 5.1).
English: The following serious adverse events were considered to be treatment related and were reported uncommonly (may affect up to 1 in 100 people), allergic reaction (such as skin rash, swelling of the face, lips and tongue, wheezing, difficulty breathing or swallowing), convulsion, irregular heart-beat, hearing impairment, shortness of breath, inflammation of the digestive tract, wheezing due to disrupted airflow.
Croatian: Za sljedeće ozbiljne nuspojave se smatra da su povezane s liječenjem i prijavljene su manje često (mogu se javiti u do 1 na 100 osoba): alergijska reakcija (kao što je kožni osip, oticanje lica, usana i jezika, zviždanje pri disanju, poteškoće s disanjem ili gutanjem), konvulzije, nepravilan rad srca, oštećenje sluha, nedostatak zraka, upala probavnog trakta, zviždanje zbog poremećenog protoka zraka.
English: Differences in 6MWD were observed between patients with primary PAH and PAH associated with connective tissue disease.
Croatian: Razlike u 6MWD-u zapažene su između bolesnika s primarnim PAH-om i bolesnika s PAH-om povezanim s bolešću vezivnog tkiva.
English: Caution is advised when sildenafil is administered to patients taking an alpha-blocker as the co-administration may lead to symptomatic hypotension in susceptible individuals (see section 4.5).
Croatian: Savjetuje se oprez kada se sildenafil primjenjuje u bolesnika koji uzimaju alfa-blokatore jer istovremena primjena može u osjetljivih osoba dovesti do simptomatske hipotenzije (vidjeti dio 4.5).
English: The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section
Croatian: Istovremena primjena s PDE5 inhibitiorima, uključujnući sildenafil, zajedno sa stimulatorima gvanilat ciklaze, kao što je riocigvat, je kontrainidicirana i može potencijalno dovesti do simptomatske hipotenzije (vidjeti dio 4.5).
English: High dose (n=27)
Croatian: Visoka doza (n = 27)
English: Film coat: hypromellose (15cp) (E464), titanium dioxide (E171), lactose monohydrate, triacetin.
Croatian: Film ovojnica: hipromeloza (15cp) (E464), titanijev dioksid (E171), laktoza hidrat, triacetin.
English: The safety and efficacy of sildenafil when co-administered with other PDE5 inhibitors has not been studied in pulmonary arterial hypertension patients (see section 4.4).
Croatian: Sigurnost i djelotvornost istovremene primjene sildenafila i drugih inhibitora PDE5 nije ispitana u bolesnika s plućnom arterijskom hipertenzijom (vidjeti dio 4.4).
English: The most common adverse reactions that occurred (with a frequency ≥1%) in sildenafil patients (combined doses) and with a frequency >1% over placebo patients were pyrexia, upper respiratory tract infection (each 11.5%), vomiting (10.9%), erection increased (including spontaneous penile erections in male subjects) (9.0%), nausea, bronchitis (each 4.6%), pharyngitis (4.0%), rhinorrhoea (3.4%), and pneumonia, rhinitis (each 2.9%).
Croatian: Najčešće nuspojave su (sa učestalošću ≥ 1 %) u bolesnika liječenih sildenafilom (u kombiniranom liječenju) i sa učestalošću > 1 % u odnosu na bolesnike na placebu bile su vrućica, infekcija gornjih dišnih puteva (svaki 11,5 %), povraćanje (10,9%), pojačana erekcija (uključujući spontanu erekciju spolovila u muških bolesnika) (9%), mučnina, bronhitis (svaki 4.6%), faringitis (4,0%), curenje iz nosa (3,4%) i pneumonija, rinitis (svaki
English: Efficacy and safety in adult patients with PAH (when used in combination with bosentan) A randomized, double-blind, placebo controlled study was conducted in 103 clinically stable subjects with PAH (WHO FC II and III) who were on bosentan therapy for a minimum of three months.
Croatian: Randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno je u 103 klinički stabilnih bolesnika s PAH-om (WHO FC II i III) koji su se liječili bosentanom najmanje tri mjeseca.
English: In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 154% and 87%, respectively in cirrhotic subjects compared to subjects with normal hepatic function.
Croatian: Osim toga, vrijednosti AUC-a i Cmax Ndezmetil metabolita bile su značajno povećane (154% odnosno 87%) u ispitanika s cirozom u odnosu na ispitanike s normalnom jetrenom funkcijom.
English: The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.
Croatian: Nije ispitivana farmakokinetika sildenafila u bolesnika s teškim oštećenjem jetrene funkcije.
English: Patients were randomised to placebo or sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day as tolerated) when used in combination with intravenous epoprostenol.
Croatian: Bolesnici su randomizirani na placebo ili sildenafil (u fiksnoj titraciji počevši od 20 mg, zatim 40 mg te na kraju 80 mg tri puta na dan, ovisno o podnošljivosti) u kombinaciji s epoprostenolom koji se primjenjivao intravenski.
English: Results were generally consistent in subgroups according to aetiology (primary and connective tissue disease-associated PAH), WHO functional class, gender, race, location, mean PAP and PVRI.
Croatian: Rezultati su u pravilu bili dosljedni u podskupinama prema etiologiji (primarni i PAH povezan s bolešću vezivnog tkiva), funkcionalnom stupnju po SZO-u, spolu, rasi, lokaciji, prosječnom plućnom arterijskom tlaku i indeksu plućnog krvožilnog otpora.
English: In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200% and 79% respectively in subjects with severe renal impairment compared to subjects with normal renal function.
Croatian: Osim toga, vrijednosti AUC-a i Cmax N-dezmetil metabolita bile su značajno povećane (200% odnosno 79%) u ispitanika s teškim oštećenjem funkcije bubrega u odnosu na ispitanike s normalnom bubrežnom funkcijom.
English: After chronic dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mm Hg respectively.
Croatian: Nakon kronične primjene doze od 80 mg tri puta na dan u bolesnika sa sistemskom hipertenzijom, srednja vrijednost promjene u odnosu na početne vrijednosti činilo je sniženje sistoličkog i dijastoličkog krvnog tlaka za 9,4 mmHg, odnosno 9,1 mmHg.
English: For patients with a baseline 6MWD <325 m improved efficacy was observed with higher doses (placebo-corrected improvements of 58 metres, 65 metres and 87 metres for 20 mg, 40 mg and 80 mg doses TID, respectively).
Croatian: U bolesnika čiji je početni 6MWD bio < 325 metara opažena je poboljšana djelotvornost kod primjene viših doza (poboljšanje korigirano za placebo za 58 metara pri dozi od 20 mg TID, za 65 metara pri dozi od 40 mg TID te za 87 metara pri dozi od 80 mg TID).
English: The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil (20 mg three times a day) and placebo (13.62 m (95% CI: -3.89 to 31.12) and 14.08 m (95% CI: -1.78 to 29.95), respectively).
Croatian: Rezultati pokazuju da nema značajne razlike u srednjoj vrijednosti promjene u 6MWD-u u odnosu na početne vrijednosti između sildenafila (20 mg tri puta na dan) i placeba (13,62 m (95% CI: -3,89 do 31,12) odnosno 14,08 m (95% CI: -1,78 do 29,95).
English: Improvements were observed with cardiac index with all three sildenafil groups over placebo, 10%, 4% and 15% for the low, medium and high dose groups respectively.
Croatian: Poboljšanja srčanog indeksa opažena su u sve tri skupine liječene sildenafilom u odnosu na placebo: 10% u skupini koja je primala nisku dozu, 4% u skupini koja je primala srednju dozu i 15% u skupini koja je primala visoku dozu sildenafila.
English: During the conduct of the study, there were a total of 42 deaths reported, whether on treatment or reported as part of the survival follow-up.
Croatian: Tijekom provođenja ispitivanja, prijavljena su ukupno 42 smrtna slučaja.
English: Common pyrexia *These adverse events/reactions have been reported in patients taking sildenafil for the treatment of male erectile dysfunction (MED).
Croatian: Opći poremećaji i reakcije na mjestu primjene često pireksija * Ove nuspojave prijavljene su u bolesnika koji su uzimali sildenafil za liječenje muške erektilne disfunkcije.
English: A total of 207 patients were treated with sildenafil in the pivotal study, and their long term survival status was assessed for a minimum of 3 years.
Croatian: U pivotalnom je ispitivanju sildenafilom liječeno ukupno 207 bolesnika te je procjenjivano njihovo dugoročno preživljenje tijekom najmanje 3 godine.
English: In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B) sildenafil clearance was reduced, resulting in increases in AUC (85%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment.
Croatian: U dobrovoljaca s blagom do umjerenom cirozom jetre (Child-Pugh stadij A i B) klirens sildenafila je bio smanjen, što je rezultiralo povećanjem AUC-a (85%) i Cmax (47%) u usporedbi s dobrovoljcima bez oštećenja funkcije jetre podudarnima s obzirom na dob.
English: In a study of healthy volunteers sildenafil at steady state (80 mg three times a day) resulted in a 50% increase in bosentan AUC (125 mg twice daily).
Croatian: U ispitivanju provedenom sa zdravim dobrovoljcima sildenafil je u stanju dinamičke ravnoteže (80 mg tri puta na dan) povećao AUC bosentana (125 mg dva puta na dan) za 50%.
English: There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration.
Croatian: Nema podataka o sigurnosti primjene sildenafila u bolesnika s poremećajima krvarenja ili aktivnim želučanim vrijedom.
English: In a placebo-controlled study of sildenafil as an adjunct to intravenous epoprostenol in pulmonary arterial hypertension, a total of 134 patients were treated with sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day, as tolerated) and epoprostenol, and 131 patients were treated with placebo and epoprostenol.
Croatian: U placebom kontroliranom ispitivanju sildenafila kao dodatka intravenskoj terapiji epoprostenolom u liječenju plućne arterijske hipertenzije, ukupno su 134 bolesnika liječena sildenafilom (u fiksnoj titraciji, počevši od 20 mg, zatim 40 mg te na kraju 80 mg tri puta na dan, ovisno o podnošljivosti) i epoprostenolom, dok je 131 bolesnik primao placebo i epoprostenol.
English: Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125 mg twice daily with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63% decrease of sildenafil AUC.
Croatian: Istovremena primjena bosentana (umjerenog induktora CYP3A4, CYP2C9, a možda i CYP2C19) u dozi od 125 mg dva puta na dan sa sildenafilom u dozi od 80 mg tri puta na dan (u stanju dinamičke ravnoteže) tijekom 6 dana u zdravih dobrovoljaca rezultirala je smanjenjem AUC-a sildenafila od 63%.
English: The PAH patients included those with primary PAH, and PAH associated with connective tissue disease.
Croatian: Bolesnici s PAH-om uključivali su one s primarnim PAH-om i one s PAH-om povezanim s bolešću vezivnog tkiva.
English: When prescribing sildenafil, physicians should carefully consider whether patients with certain underlying conditions could be adversely affected by sildenafil's mild to moderate vasodilatory effects, for example patients with hypotension, patients with fluid depletion, severe left ventricular outflow obstruction or autonomic dysfunction (see section 4.4).
Croatian: Kad propisuju sildenafil, liječnici trebaju pažljivo razmotriti hoće li blagi do umjereni vazodilatacijski učinci sildenafila štetno utjecati na bolesnike s određenim podležećim stanjima, kao što su hipotenzija, gubitak tekućine, teška opstrukcija istisnog dijela lijeve klijetke ili autonomna disfunkcija (vidjeti dio
English: In volunteers with severe renal impairment (creatinine clearance <30 ml/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88% respectively compared to age-matched volunteers with no renal impairment.
Croatian: U dobrovoljaca s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) klirens sildenafila je bio smanjen, što je rezultiralo srednjom vrijednošću povećanja AUC-a od 100%, a Cmax od 88% u usporedbi s dobrovoljcima bez oštećenja funkcije bubrega podudarnima s obzirom na dob.
English: Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease (see section 5.1).
Croatian: Djelotvornost u smislu poboljšanja tjelesne sposobnosti ili plućne hemodinamike dokazana je u primarnoj plućnoj hipertenziji i plućnoj hipertenziji povezanoj s urođenom srčanom bolešću (vidjeti dio
English: Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route).
Croatian: Sildenafil se prvenstveno metabolizira posredstvom izoformi (CYP) 3A4 (glavni put) i 2C9 (manji put) citokroma P450.